LMNX - ルミネックス (Luminex Corporation) ルミネックス

 LMNXのチャート


 LMNXの企業情報

symbol LMNx
会社名 Luminex Corp (ルミネックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 ルミネックス(Luminex Corporation)は診断、医薬品、ライフサイエンス業界全体のアプリケーションで生物学的検査技術を開発、製造、販売する。同社の製品は、ヒト遺伝学、パーソナライズド・メディスン、感染症などの分子診断検査市場に焦点を当てる。同社は100プレックスのテストを提供するLUMINEX 100/200システムを含むxMAP技術を使用した多様な計測器を有する。同社のFLEXMAP 3Dシステムは、ハイスループット500ポールの検査システムであり、MAGPIXシステムは、フローサイトメトリーではなくイメージングを使用して50プレックスの検査を提供する。エンドユーザーは、xMAP技術を使用することにより、1サンプルにつき複数の結果を同時に生成することができる。同社は主に、検査機器と検査法を含む製品を検査ラボに販売することにより、診断、製薬およびライフサイエンス産業を提供する。   ルミネックスは、バイオテクノロジ―検査技術を開発する米国の会社。臨床診断およびライフサイエンス産業向けアプリケ―ションを開発、製造、販売する。同社のマルチ分析物プロファイリング「xMAP」技術は、多数のバイオアッセイ(生物を用いた化学物質の評価)の同時分析を可能にする。事業は、テクノロジ―と戦略パ―トナ―シップの2部門で構成。   The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.
本社所在地 12212 Technology Blvd. Austin TX 78727 USA
代表者氏名 George Walter Loewenbaum ジョージ・ウォルター・ローウェンバウム
代表者役職名 Independent Chairman of the Board
電話番号 +1 512-249-4741
設立年月日 34820
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 896人
url www.luminexcorp.com
nasdaq_url https://www.nasdaq.com/symbol/lmnx
adr_tso
EBITDA EBITDA(百万ドル) 62.17700
終値(lastsale) 27.34
時価総額(marketcap) 1219593573.98
時価総額 時価総額(百万ドル) 1267.325
売上高 売上高(百万ドル) 314.57500
企業価値(EV) 企業価値(EV)(百万ドル) 1128.329
当期純利益 当期純利益(百万ドル) 50.46900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Luminex Corporation revenues increased 5% to $162.2M. Net income applicable to common stockholders excluding extraordinary items increased 62% to $23.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Research and development other decrease of 9% to $21.8M (expense) Other income (expense).

 LMNXのテクニカル分析


 LMNXのニュース

   Nuance, Luminex rise; United Airlines, Ingersoll Rand fall  2021/04/12 20:21:00 ABC News
Stocks that traded heavily or had substantial price changes Monday: Nuance, Luminex rise; United Airlines, Ingersoll Rand fall
   Luminex Jumps on $1.8 Billion Deal from Italy’s DiaSorin  2021/04/12 15:36:31 Investing.com
https://www.investing.com/news/stock-market-news/luminex-jumps-on-18-billion-deal-from-italys-diasorin-2472041
   DiaSorin Acquires COVID-19 Test Maker Luminex For $37 Per Share  2021/04/12 11:37:38 Benzinga
Italian diagnostics firm DiaSorin SpA (OTCMKTS: DSRLF) has agreed to acquire Luminex Corporation (NASDAQ: LMNX ) for $37 per share in an all-cash transaction, corresponding to a total equity value of approximately $1.8 billion. The offer price represents around 23.1% premium to Luminex shareholders based on the unaffected closing stock price of Luminex on 24 February (the date before press rumors regarding a potential sale of the company). Luminex makes COVID-19 laboratory tests along … Full story available on Benzinga.com
   Luminex Submits Joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA for Emergency Use Authorization  2021/03/10 11:30:00 PR Newswire
AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for the company's new multi-analyte respiratory panel combining Flu A/B and…
   Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG® Respiratory Panel Test Including SARS-CoV-2  2021/03/04 11:30:00 PR Newswire
AUSTIN, Texas, March 4, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) that includes…
   Luminex Home Décor & Fragrance Hires Seasoned Consumer Products CEO  2020/08/27 10:15:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Luminex Announces Scott Meader as CEO
   Luminex Announces Graduation to OTCQX Best Market in the U.S. under the Symbol LUMIF  2020/08/18 11:00:00 PR Newswire
VANCOUVER, BC, Aug. 18, 2020 /PRNewswire/ - Luminex Resources Corp. (TSXV: LR) (OTCQX: LUMIF) (the "Company" or "Luminex") is pleased to announce that its common shares are now trading on the OTCQX Best Market, a U.S. market operated by OTC Markets Group in New York, under the symbol…
   Global Genomics Market Outlook 2020-2025; Dominated by Illumina, Thermo Fisher Scientific, Agilent Technologies, Luminex Corporation and Myriad Genetics - ResearchAndMarkets.com  2020/08/13 15:31:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Genomics Market - Growth, Trends, and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering. The Global Genomics Market is anticipated to grow at a CAGR of 9.3% during the forecast period. The major factors attributing to the growth of the genomics market are growing government support and increased number of genomics studies, declining sequencing cost, increased genomics applications. The genomics market is geared to exponential growth
   Vaccine Execs Rake In $1 Billion In Stock Sales As Positive Headlines Boost Shares  2020/07/27 19:13:35 Zero Hedge
Vaccine Execs Rake In $1 Billion In Stock Sales As Positive Headlines Boost Shares Tyler Durden Mon, 07/27/2020 - 15:13 With the race to find a vaccine for COVID-19 in full effect, biotech executives and other insiders from at least 11 companies have made hand over fist - raking in over $1 billion in stock sales after announcing positive developments, according to the New York Times . In some cases, company insiders are profiting from regularly scheduled compensation or automatic stock trades. But in other situations, senior officials appear to be pouncing on opportunities to cash out while their stock prices are sky high . And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. -NYT In May, we noted that insiders at Moderna cashed out on some $30 million in options - while CEO Stephane Bancel has become a billionaire. Moderna CEO Stéphane Bancel The company's market value is now nearly $30 billion thanks to a stream of positive press releases, while insiders have sold around $248 million altogether since January - most of it coming following an April announcement that the company had been selected to receive federal funding to support their efforts. 1/ It is good to be Stephane Bancel, CEO of Moderna.
   Luminex Files for Emergency Use Authorization for Expanded NxTAG Respiratory Panel Test Including SARS-CoV-2  2020/07/22 09:00:00 PR Newswire
AUSTIN, Texas, July 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an EUA request to the FDA for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) to include the SARS-CoV-2 virus for high-throughput COVID-19 testing….
   Luminex Files for Emergency Use Authorization for Expanded NxTAG Respiratory Panel Test Including SARS-CoV-2  2020/07/22 09:00:00 PR Newswire
AUSTIN, Texas, July 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an EUA request to the FDA for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) to include the SARS-CoV-2 virus for high-throughput COVID-19 testing….
   Luminex Corporation Second Quarter Earnings Release Rescheduled for August 4, 2020  2020/07/20 17:16:00 PR Newswire
AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2020 on Tuesday, August 4, 2020. A press release announcing the results is scheduled for release after the close of trading…
   Luminex Receives FDA Emergency Use Authorization for COVID-19 Antibody Test  2020/07/20 09:00:00 PR Newswire
AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the company's xMAP® SARS-CoV-2 Multi-Antigen IgG Assay. Clinical laboratories can now use this…
   Luminex Corporation Pre-Release of 2nd Quarter 2020 Revenue  2020/07/08 11:00:00 PR Newswire
AUSTIN, Texas, July 8, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter of 2019. Highlights include: Molecular Diagnostics revenue of approximately $65 million, up over…
   Luminex Submits Emergency Use Authorization Request to U.S. FDA for COVID-19 Antibody Test  2020/06/29 20:01:00 PR Newswire
AUSTIN, Texas, June 29, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for its xMAP® SARS-CoV-2 Multi-Antigen IgG assay. The assay was developed to…

 関連キーワード  (先端医療機器_テクノロジ― 米国株 ルミネックス LMNX Luminex Corporation)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)